{"nct_id":"NCT05590403","title":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above","status":"COMPLETED","status_verified_date":"2025-02","start_date":"2022-10-28","start_date_type":"ACTUAL","primary_completion_date":"2023-03-13","primary_completion_date_type":"ACTUAL","completion_date":"2024-02-12","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["GSK"]}